The partnership began in 2024, when Geistlich appointed StimLabs as the exclusive distributor of its wound care portfolio in the United States starting with the advanced wound matrix Derma-Gide®. With the launch of the new product, this partnership is now being further deepened. DermaForm™ is a particulate collagen product for chronic and acute wounds, developed and manufactured by Geistlich in Wolhusen. The unique particulate format allows for a versatile application process and conforms to large, irregular and complex wounds. The new product received 510(k) clearance from the FDA last week.
Mark Spilker, Chief Science Officer at Geistlich, says: “Geistlich developed DermaForm™ by applying our regeneration expertise to expand upon the proven clinical performance of Derma-Gide® now with a new particulate form for ease of use.”
Shared mission: improving patients’ quality of life
At the core of the partnership lies a clear, shared mission: to meaningfully improve the quality of life for people living with complex wounds. “Geistlich has continued to demonstrate their skill in innovation and commitment to quality, which are core values at StimLabs,” says John Daniel, Founder and CEO of StimLabs. “We look forward to working with them to bring another unique solution to our patients and providers.”
“DermaForm™ is the start of building together an attractive portfolio of innovative solutions for clinicians to effectively treat more patients. By leveraging our research innovation with StimLabs’ commercial strength, this partnership is poised to set new standards in regenerative medicine.”, says David Wemans, VP Regenerative Technologies at Geistlich.